|Bid||3.8000 x 28000|
|Ask||4.0000 x 1200|
|Day's range||3.8000 - 4.0000|
|52-week range||2.4900 - 5.4400|
|Beta (5Y monthly)||1.93|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2022 - 15 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.00|
Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.
As a reminder, this call is being recorded on May 5, 2022, and will be available for playback on the MannKind Corporation's website shortly after the conclusion of this call until May 19, 2022. Joining us today from MannKind are chief executive officer, Michael Castagna; and chief financial officer, Steven Binder.